@misc{10481/73198,
year = {2021},
month = {12},
url = {http://hdl.handle.net/10481/73198},
abstract = {Background: Non-alcoholic fatty liver disease (NAFLD) and idiosyncratic drug-induced liver injury (DILI) could share molecular mechanisms involving the immune system. We aimed to identify activation immunological biomarkers in invariant natural killer T (iNKT) and CD4/CD8+ T cells in NAFLD and DILI. Methods: We analyzed the activation profile (CD69, CD25, and HLA-DR) and natural killer group 2 member D (NKG2D) on iNKT cells, and CD4/CD8 T cells in peripheral blood mononuclear cells from NAFLD, with or without significant liver fibrosis, and DILI patients. Results: There was an increase in iNKT cells in NAFLD patients compared to DILI or control subjects. Regarding the cellular activation profile, NAFLD with significant liver fibrosis (F >= 2) displayed higher levels of CD69+iNKT cells compared to NAFLD with none or mild liver fibrosis (F <= 1) and control patients. CD69+iNKT positively correlated with insulin resistance, aspartate aminotransferase (AST) level, liver fibrosis-4 index (FIB4) and AST to Platelet Ratio Index (APRI). DILI patients showed an increase in CD69+ and HLA-DR+ in both CD4+ and CD8+ T cells, detecting the most relevant difference in the case of CD69+CD8+ T cells. Conclusions: CD69+iNKT may be a biomarker to assess liver fibrosis progression in NAFLD. CD69+CD8+ T cells were identified as a potential distinctive biomarker for distinguishing DILI from NAFLD.},
organization = {Instituto de Salud Carlos III	PI18/01804	
PI19/00883	
PI21/01248},
organization = {Junta de Andalucia	UMA18-FEDERJA-194	
PI18-RT-3364	
PI-0285-2016},
organization = {FEDER funds ("A way to make Europe") ("Andalucia se mueve con Europa")},
publisher = {MDPI},
keywords = {Non-alcoholic fatty liver disease (NAFLD)},
keywords = {Drug-induced liver injury (DILI)},
keywords = {Immunophenotype},
keywords = {Immune response},
keywords = {Liver fibrosis},
title = {Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury},
doi = {10.3390/biomedicines10010055},
author = {Caballano Infantes, Estefanía and Ruiz-Cabello Osuna, Francisco},
}